Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects

This publication has 71 references indexed in Scilit:

• Dexrazoxane-Associated Risk for Secondary Malignancies in Pediatric Hodgkin's Disease: A Claim Without Compelling Evidence
  Journal of Clinical Oncology, 2007
• SFOP OS94: A randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients
  European Journal of Cancer, 2007
• Dexrazoxane-Associated Risk for Acute Myeloid Leukemia/Myelodysplastic Syndrome and Other Secondary Malignancies in Pediatric Hodgkin's Disease
  Journal of Clinical Oncology, 2007
• Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia
  Blood, 2006
• Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: A report from the late effects surveillance system
  Pediatric Blood & Cancer, 2006
• Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose
  European Journal of Cancer, 2004
• High‐dose ifosfamide in relapsed pediatric osteosarcoma: Therapeutic effects and renal toxicity
  Pediatric Blood & Cancer, 2004
• Partial reversibility of cisplatin nephrotoxicity in children
  The Journal of Pediatrics, 1991
• Protective Effect of the Bispiperazinedione ICRF-187 against Doxorubicin-Induced Cardiac Toxicity in Women with Advanced Breast Cancer
  New England Journal of Medicine, 1988
• The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the Extremity
  New England Journal of Medicine, 1986